Ferric carboxymaltose

Generic Name: Ferric carboxymaltose

Brand Names: Injectafer

Drug Type: Small Molecule

CAS Number: 9007-72-1

Unique Ingredient Identifier: 6897GXD6OE

Background: Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Indication: Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.

Associated Conditions: Iron Deficiency Anemia (IDA)

Clinical Trials

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

Phase 4

Recruiting

Conditions: Myocardial Infarction, Acute

Interventions: Drug: Sodium Chloride 0.9% Inj
Drug: Ferinject

First Posted Date: 2023-03-08

Last Posted Date: 2023-09-21

Lead Sponsor: Wroclaw Medical University

Target Recruit Count: 2000

Registration Number: NCT05759078

Locations: 🇵🇱
Ośrodek Kardiologii Inwazyjnej IKARDIA Sp. z o.o., Nałęczów, Lubelskie, Poland
🇵🇱
Zespół Opieki Zdrowotnej w Kłodzku, Kłodzko, Dolnośląskie, Poland
🇵🇱
4Cardia Sp. z o.o., Kraśnik, Lubelskie, Poland

and more 32 locations

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Phase 3

Recruiting

Conditions: Surgery
Liver Metastases
Liver Cancer
Pancreas Cancer
Aortic Aneurysm

Interventions: Drug: Placebo
Drug: Ferric carboxymaltose

First Posted Date: 2023-02-24

Last Posted Date: 2024-10-21

Lead Sponsor: Jon Unosson

Target Recruit Count: 338

Registration Number: NCT05744219

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sverige, Sweden

Impact of Intravenous Iron on Musculoskeletal Function in Older Adults

Phase 4

Not yet recruiting

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferrous Sulfate 200 MG
Drug: Ferinject

First Posted Date: 2023-02-01

Last Posted Date: 2023-02-01

Lead Sponsor: Liverpool Hope University

Target Recruit Count: 100

Registration Number: NCT05708170

Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency

Phase 4

Not yet recruiting

Conditions: Heart Failure NYHA Class III
Heart Failure NYHA Class II
Heart Failure, Systolic
Heart Failure
Iron-deficiency
Vitamin D Deficiency

Interventions: Drug: Sucrosomial iron
Drug: Ferric Carboxymaltose 50 MG/ML
Drug: Vitamin D

First Posted Date: 2023-01-27

Last Posted Date: 2023-12-15

Lead Sponsor: University of Padova

Target Recruit Count: 258

Registration Number: NCT05702970

Neuroimaging Ancillary Study

Completed

Conditions: Iron Deficiency Anemia
Iron Deficiency Anemia of Pregnancy
Child Development
Neurodevelopmental Disorder of Foetus
Iron Deficiency Anemia Treatment
Fetal Neurodevelopmental Disorder

Interventions: Drug: Ferric Sulfate
Drug: Ferric carboxymaltose
Drug: Iron isomaltoside

First Posted Date: 2022-09-19

Last Posted Date: 2025-04-16

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 184

Registration Number: NCT05545527

Locations: 🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India

Management of Preoperative Anaemia in Surgical Oncology

Phase 4

Conditions: Anemia
Tumor

Interventions: Drug: Ferric Carboxymaltose Injection
Drug: Folic acid
Drug: B12

First Posted Date: 2022-08-17

Last Posted Date: 2022-08-19

Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Target Recruit Count: 500

Registration Number: NCT05505006

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

Active, not recruiting

Conditions: Iron Deficiency Anemia
Neurodevelopmental Abnormality
Autism Spectrum Disorder

Interventions: Drug: Ferric carboxymaltose
Drug: Iron isomaltoside
Drug: Ferric Sulfate

First Posted Date: 2022-08-17

Last Posted Date: 2023-11-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 538

Registration Number: NCT05504863

Locations: 🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
🇮🇳
S. Nijalingappa Medical College, Bagalkot, Karnataka, India
🇮🇳
Raichur Institute of Medical Sciences, Raichur, Karnataka, India

Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction

Phase 4

Withdrawn

Conditions: Heart Failure With Normal Ejection Fraction
Iron-deficiency

Interventions: Drug: Placebo
Drug: Ferric carboxymaltose

First Posted Date: 2022-07-28

Last Posted Date: 2022-07-28

Lead Sponsor: Cantonal Hosptal, Baselland

Registration Number: NCT05477498

Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery

Phase 4

Recruiting

Conditions: Hip Fractures

Interventions: Drug: Ferinject
Drug: Normal saline

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 264

Registration Number: NCT05429749

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Phase 4

Completed

Conditions: Infant, Low Birth Weight
Anemia of Pregnancy
Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose
Drug: Iron isomaltoside
Drug: Ferric Sulfate

First Posted Date: 2022-05-03

Last Posted Date: 2024-05-24

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4368

Registration Number: NCT05358509

Locations: 🇮🇳
Sawai Man Singh Medical College, Jaipur, Rajasthan, India
🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
🇮🇳
Raichur Institute of Medical Sciences, Raichur, Karnataka, India

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy